Related Experiment Videos
Meloxicam inhibits the growth of colorectal cancer cells
A P Goldman1, C S Williams, H Sheng
1Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Abstract:
Cyclooxygenase-2 has been reported to play an important role in colorectal carcinogenesis. The effects of meloxicam (a COX-2 inhibitor) on the growth of two colon cancer cell lines that express COX-2 (HCA-7 and Moser-S) and a COX-2 negative cell line (HCT-116) were evaluated. The growth rate of these cells was measured following treatment with meloxicam. HCA-7 and Moser-S colony size were significantly reduced following treatment with meloxicam; however, there was no significant change in HCT-116 colony size with treatment. In vivo studies were performed to evaluate the effect of meloxicam on the growth of HCA-7 cells when xenografted into nude mice. We observed a 51% reduction in tumor size after 4 weeks of treatment. Analysis of COX-1 and COX-2 protein levels in HCA-7 tumor lysates revealed a slight decrease in COX-2 expression levels in tumors taken from mice treated with meloxicam and no detectable COX-1 expression. Here we report that meloxicam significantly inhibited HCA-7 colony and tumor growth but had no effect on the growth of the COX-2 negative HCT-116 cells.
Insights
Meloxicam, a cyclooxygenase-2 (COX-2) inhibitor, significantly reduced colon cancer cell growth and tumor size in vivo. This COX-2 inhibitor showed no effect on COX-2 negative cells, highlighting its targeted anti-cancer potential.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Cyclooxygenase-2 (COX-2) is implicated in colorectal cancer development.
- Targeting COX-2 is a potential strategy for cancer therapy.
Purpose of the Study:
- To evaluate the anti-cancer effects of meloxicam, a COX-2 inhibitor, on colon cancer cell lines.
- To determine if meloxicam's efficacy is dependent on COX-2 expression.
Main Methods:
- In vitro studies using HCA-7, Moser-S (COX-2 positive), and HCT-116 (COX-2 negative) colon cancer cell lines.
- Treatment with meloxicam and measurement of cell growth and colony size.
- In vivo xenograft studies using HCA-7 cells in nude mice, followed by tumor size measurement and protein analysis.
Main Results:
- Meloxicam significantly inhibited the growth of HCA-7 and Moser-S colon cancer cells.
- No significant effect on the growth of COX-2 negative HCT-116 cells was observed.
- In vivo, meloxicam treatment resulted in a 51% reduction in HCA-7 tumor size after 4 weeks, with decreased COX-2 expression.
Conclusions:
- Meloxicam demonstrates significant anti-proliferative effects on COX-2 expressing colon cancer cells both in vitro and in vivo.
- The findings suggest that meloxicam's anti-cancer activity is COX-2 dependent.
- Meloxicam holds promise as a targeted therapy for colorectal cancer.